Background
Methods
Echocardiography
Stress test
Holter monitoring
Definitions
Syncope
Premature sudden death
Non-sustained ventricular tachycardia
Abnormal blood pressure response
Risk factors
Statistical analysis
Results
Age, years | 52.3 ± 15.6 (16 to 83) |
---|---|
Age of initial diagnosis, years | 48.3 ± 16.4 (5 to 81) |
Male gender | 82 (66.6%) |
Referral patients | 68 (55.8%) |
Non-referral patients | 55 (44.7%) |
Clinical status | |
Asymptomatic | 56(45.5%) |
Symptomatic | 67 (54.5%) |
Patients with NYHA class II | 52 (42.2%) |
Patients with NYHA class III/IV | 15(12.1%) |
Family history of premature SD | 8 (6.5%) |
Syncope | 17 (13.8%) |
ABPR | 30 (24.4%) |
NSVT | 17 (13.8%) |
Atrial fibrillation | |
Paroxysmal | 11 (8.9%) |
Permanent | 7 (5.7%) |
Progression to Dilated Cardiomyopathy | 9 (7.3%) |
ECG | |
Normal | 12 (9.8%) |
Abnormal | 111 (90.2%) |
Other disease | |
Coronary artery disease | 6 (4.8%) |
Diabetes | 6 (4.8%) |
Hypertension | 17 (13.8%) |
Echocardiographic data
Left ventricular end diastolic diameter, cm | 4.32 ± 0.79 (2.77 to 7.05) |
---|---|
Left ventricular maximum wall thickness, cm | 2.16 ± 0.57 (1.42 to 3.87) |
Left ventricular ejection fraction, % | 71.7 ± 13 (30 to 90) |
Left atrium size, cm | 4.09 ± 0.68 (2.24 to 5.90) |
Patients with basal gradient ≥30 mmHg | 27 (21.9%) (range 32 to 230 mmHg). |
Patients with maximum wall thickness ≥30 mm | 15 (12.2%) |
Medical treatment
Medication | 80 (65%) |
---|---|
b-blocker | 59 (47.9%) |
verapamil | 4 (3.2%) |
disopyramide | 3 (2.4%) |
amiodaron | 10 (8.1%) |
diltiazem | 5 (4%) |
warfarin | 9 (7.3%) |
CEI/ARBs | 13 (10.5%) |
Statins | 13 (10.5%) |
Diuretics | 8 (6.5%) |
Digoxin | 2 (1.6%) |
Aspirin/clopidogrel | 16 (13%) |
No Medication
| 43 (35%) |